News Vertex weakens after neuropathic pain trial reads out A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data.
News Vertex eyes FDA decision on non-opioid pain drug in January Vertex Pharma has filed for FDA approval of its non-opioid pain drug suzetrigine, starting the clock ticking on a review that should be completed early next year.
R&D Non-opioid painkillers: Another tool to fight the opioid epi... The opioid epidemic is still an ongoing problem and there is no single solution to bring it under control.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.